National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

human monoclonal antibody 216
A naturally-occurring human IgM monoclonal antibody with potential antineoplastic activity. Human monoclonal antibody 216, derived from the gene VH4-34, binds to the glycosylated epitope CDIM on the surface of both malignant and normal B cells. Upon binding to B cells, this antibody may crosslink two or more CDIM molecules, resulting in the formation of cell membrane pores, the disruption of cell membrane integrity, and B cell lysis; this mechanism of antibody-mediated cell death is direct and does not involve mechanisms of complement-mediated cytotoxicity or antibody-depndent cell-mediated cytotoxicity (ADCC). CDIM is the glyco-moiety of a 75 kD MW B-cell cell surface glycoprotein. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Abbreviation:MoAb 216



Previous:huBC1-huIL12 fusion protein AS1409, HuC242-DM4, human anti-alpha-v integrin monoclonal antibody, human anti-TGF-beta monoclonal antibody GC1008, human gp100 plasmid DNA vaccine
Next:human monoclonal antibody B11-hCG beta fusion protein CDX-1307, human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, human prostate-specific membrane antigen plasmid DNA vaccine, HuMax-CD38, Hycamtin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov